Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting

While molnupiravir (MOV) and nirmatrelvir–ritonavir (NMV-r) were developed for treatment of mild to moderate COVID-19 infection, there has been a lack of data on the efficacy among unvaccinated adult patients with chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwok, Wang Chun, Tsoi, Man Fung, Leung, Sze Him Isaac, Tsui, Chung Ki, Tam, Terence Chi Chun, Ho, James Chung Man, Lam, David Chi Leung, Ip, Mary Sau Man, Ho, Pak Leung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055981/
https://www.ncbi.nlm.nih.gov/pubmed/36992319
http://dx.doi.org/10.3390/v15030610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055981/
https://www.ncbi.nlm.nih.gov/pubmed/36992319
http://dx.doi.org/10.3390/v15030610

Ejemplares similares